{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:13:08Z","timestamp":1786993988399,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008309","name":"Johns Hopkins Bloomberg School of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008309","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32 HL007024"],"award-info":[{"award-number":["T32 HL007024"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK100446"],"award-info":[{"award-number":["R01 DK100446"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK115534"],"award-info":[{"award-number":["R01 DK115534"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01 FD004977-02"],"award-info":[{"award-number":["U01 FD004977-02"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["K23 DK106515"],"award-info":[{"award-number":["K23 DK106515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["K01 DK121825"],"award-info":[{"award-number":["K01 DK121825"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mayocp.2020.03.035","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T19:40:40Z","timestamp":1604346040000},"page":"2408-2419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-1631","authenticated-orcid":false,"given":"Alex M.","family":"Secora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Im","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-7744","authenticated-orcid":false,"given":"Yao","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-6023","authenticated-orcid":false,"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2020.03.035_bib1","unstructured":"Aldactone label (Spironolactone). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/012151s075lbl.pdf. Accessed August 22,\u00a02019."},{"issue":"10","key":"10.1016\/j.mayocp.2020.03.035_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"35","key":"10.1016\/j.mayocp.2020.03.035_bib3","doi-asserted-by":"crossref","first-page":"e11942","DOI":"10.1097\/MD.0000000000011942","article-title":"Effects of spironolactone in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials","volume":"97","author":"Li","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"15","key":"10.1016\/j.mayocp.2020.03.035_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2020.03.035_bib5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/HYPERTENSIONAHA.108.128017","article-title":"Hyperkalemia risk in chronic kidney disease: Deterrent to the use of aldosterone receptor antagonism or not","volume":"53","author":"Sica","year":"2009","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.mayocp.2020.03.035_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrneph.2011.175","article-title":"Diuretic use in renal disease","volume":"8","author":"Sica","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.mayocp.2020.03.035_bib7","first-page":"357","article-title":"Hyperkalemia associated with spironolactone therapy","volume":"51","author":"Dolovich","year":"2005","journal-title":"Can Fam Physician"},{"issue":"2","key":"10.1016\/j.mayocp.2020.03.035_bib8","doi-asserted-by":"crossref","first-page":"c77","DOI":"10.1159\/000097658","article-title":"Incidence and predictors of development of acute renal failure related to treatment of congestive heart failure with ACE inhibitors","volume":"105","author":"Cruz","year":"2007","journal-title":"Nephron Clin Pract"},{"issue":"3","key":"10.1016\/j.mayocp.2020.03.035_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","article-title":"The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease","volume":"73","author":"Edwards","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.035_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","article-title":"Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure","volume":"148","author":"Tamirisa","year":"2004","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.mayocp.2020.03.035_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.mayocp.2020.03.035_bib12","doi-asserted-by":"crossref","first-page":"c1768","DOI":"10.1136\/bmj.c1768","article-title":"Spironolactone use and renal toxicity: population based longitudinal analysis","volume":"340","author":"Wei","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.mayocp.2020.03.035_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","article-title":"How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?","volume":"10","author":"Svensson","year":"2004","journal-title":"J\u00a0Card Fail"},{"issue":"8","key":"10.1016\/j.mayocp.2020.03.035_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"Yancy","year":"2017","journal-title":"J\u00a0Card Fail"},{"issue":"16","key":"10.1016\/j.mayocp.2020.03.035_bib15","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.mayocp.2020.03.035_bib16","doi-asserted-by":"crossref","first-page":"e002268","DOI":"10.1161\/JAHA.115.002268","article-title":"Temporal trends and hospital variation in mineralocorticoid receptor antagonist use in veterans discharged with heart failure","volume":"4","author":"Dev","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.mayocp.2020.03.035_bib17","unstructured":"NCT03020303; NCT03682497; NCT01848639; NCT02901184. ClinicalTrials.gov Accessed April 9, 2019."},{"key":"10.1016\/j.mayocp.2020.03.035_bib18","series-title":"Health Services Research Methodology: A Focus on AIDS","first-page":"113","article-title":"The analysis of randomized and nonrandomized AIDS treatment trials using a new approach to causal inference in longitudinal studies","author":"Robins","year":"1989"},{"issue":"4","key":"10.1016\/j.mayocp.2020.03.035_bib19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.0006-341X.2005.454_7.x","article-title":"Discussion on \"statistical issues arising in the women\u2019s health initiative","volume":"61","author":"Hern\u00e1n","year":"2005","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.mayocp.2020.03.035_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0962280211403603","article-title":"Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease","volume":"22","author":"Danaei","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.035_bib21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: An application to postmenopausal hormone therapy and coronary heart disease","volume":"19","author":"Hernan","year":"2008","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.mayocp.2020.03.035_bib22","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.035_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.mayocp.2020.03.035_bib24","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"446","key":"10.1016\/j.mayocp.2020.03.035_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"9","key":"10.1016\/j.mayocp.2020.03.035_bib26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.amjcard.2013.06.039","article-title":"Effectiveness and safety of spironolactone for systolic heart failure","volume":"112","author":"Lee","year":"2013","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.mayocp.2020.03.035_bib27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer","year":"2014","journal-title":"J\u00a0Card Fail"},{"issue":"1","key":"10.1016\/j.mayocp.2020.03.035_bib28","doi-asserted-by":"crossref","first-page":"e002612","DOI":"10.1161\/JAHA.115.002612","article-title":"Effectiveness and safety of aldosterone antagonist therapy use among older patients with reduced ejection fraction after acute myocardial infarction","volume":"5","author":"Wang","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.mayocp.2020.03.035_bib29","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.035_bib30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/HJH.0b013e32835f955c","article-title":"Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients","volume":"31","author":"Flevari","year":"2013","journal-title":"J\u00a0Hypertens"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.035_bib31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2020.03.035_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jch.12628","article-title":"Long-term effects of low-dose spironolactone on chronic dialysis patients: A randomized placebo-controlled study","volume":"18","author":"Lin","year":"2016","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"9","key":"10.1016\/j.mayocp.2020.03.035_bib33","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s11255-016-1319-7","article-title":"Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis","volume":"48","author":"Lu","year":"2016","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1016\/j.mayocp.2020.03.035_bib34","first-page":"794","article-title":"Effects of spironolactone on cardiovascularoutcomes in chronic kidney disease and end-stage renal disease patients","volume":"9","author":"Sun","year":"2016","journal-title":"Int J of Clin and Exp Med"},{"issue":"2","key":"10.1016\/j.mayocp.2020.03.035_bib35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MAJ.0000000000000514","article-title":"Heart failure and chronic kidney disease: should we use spironolactone?","volume":"350","author":"Agrawal","year":"2015","journal-title":"Am J Med Sci"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.035_bib36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","article-title":"Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: A multicenter, randomized clinical trial","volume":"19","author":"Kato","year":"2015","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.035_bib37","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.mayocp.2020.03.035_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/psb.736","article-title":"Loop and potassium-sparing diuretics: their use in hypertension","volume":"22","year":"2011","journal-title":"Prescriber"},{"issue":"4","key":"10.1016\/j.mayocp.2020.03.035_bib39","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2215\/CJN.00120106","article-title":"Aldosterone antagonism in chronic kidney disease","volume":"1","author":"Ponda","year":"2006","journal-title":"CJASN"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.035_bib40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: A randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2020.03.035_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/jhh.2014.27","article-title":"Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension","volume":"29","author":"Oxlund","year":"2015","journal-title":"J\u00a0Hum Hypertens"},{"issue":"1","key":"10.1016\/j.mayocp.2020.03.035_bib42","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.035_bib43","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1159\/000368470","article-title":"Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with proteinuria","volume":"39","author":"Kim","year":"2014","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"10.1016\/j.mayocp.2020.03.035_bib44","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MNH.0000000000000051","article-title":"Is there a new dawn for selective mineralocorticoid receptor antagonism?","volume":"23","author":"Luther","year":"2014","journal-title":"Current Opinion in Nephrol and Hypertension"},{"issue":"1","key":"10.1016\/j.mayocp.2020.03.035_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1470320313481485","article-title":"Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy","volume":"16","author":"Momeni","year":"2015","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"issue":"3","key":"10.1016\/j.mayocp.2020.03.035_bib46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/nep.12188","article-title":"The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial","volume":"19","author":"Ferreira","year":"2014","journal-title":"Nephrology (Carlton)"},{"issue":"10","key":"10.1016\/j.mayocp.2020.03.035_bib47","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.035_bib48","doi-asserted-by":"crossref","first-page":"e002011","DOI":"10.1136\/bmjopen-2012-002011","article-title":"Validity of the international classification of diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission","volume":"2","author":"Fleet","year":"2012","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.mayocp.2020.03.035_bib49","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2215\/CJN.07650713","article-title":"Performance and limitations of administrative data in the identification of AKI","volume":"9","author":"Grams","year":"2014","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619620304043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619620304043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:33:25Z","timestamp":1758418405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619620304043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0025619620304043"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2020.03.035","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2020.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}